Product(s)

Capridine-Beta (and other related nitroacridine derivatives)

Indication

Prostate Cancer

Product Description

A chemotherapeutic compound; a nitroacridine derivative

Mode of Action

DNA binding agent and photosensitizer with specificity for prostate cancer, without causing bone marrow toxicity

Patient Population

First-line treatment for both androgen-dependent and androgen-independent prostate cancers

Annual Cases

200,000 (U.S.)

Expedited Review

Potentially

Current Phase

Pre-clinical - IND filing in early 2010 - due to start-up time for cGMP manufacturing

Est. Development Cost to Approval

TBD

Years to NDA filing

5+

Est. Approval

2015

Patent expiration

2021 (+ extensions)

Current Therapies

Surgery, radiation, hormone, chemotherapy

Total Market Size

$5B (U.S.)

Est. Peak Sales

$500-750M (U.S.)